{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.0","upperLimit":"19.6","value":"10.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"description":"Duration of progression free survival (median) (months)","dispersionType":"80% Confidence Interval","groups":[{"description":"Patients receive paclitaxel IV over 3 hours on day 1. Treatment continues every 21 days in the absence of disease progression or unacceptable toxicity.\n\nPaclitaxel: Given IV","id":"OG000","title":"Treatment (Paclitaxel)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"The period from study entry until disease progression, death or date of last contact","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"Months"}